green light

Houston blockchain-enabled investment platform gets regulatory approval

Houston-based iownit.us got the green light from the Financial Industry Regulatory Authority. Getty Images

For Rashad Kurbanov, this day has been a long time coming. The founder of iownit.us has been building his digital investment platform for two years, and now the company has been approved for membership by the Financial Industry Regulatory Authority.

As a FIRA member, IOI Capital and Markets LLC, a wholly owned subsidiary of iownit.us, the company can be placement agent for digital private securities that are issued on the iownit.us platform.

The iownit.us' blockchain-backed technology allows for a more simplified and streamlined process for securities investment, making it easier on both the investors and the companies seeking investment.

"We believe our platform will reduce friction in the market and reduce costs for all market participants, while importantly providing appropriate investor protections," Kurbanov says in the release.

Kurbanov indicates in the release that the length of the approval process wasn't that surprising.

"As any new technology being introduced in financial markets, blockchain had to be thoroughly evaluated by the regulators to ensure its application in compliance with regulations that made the U.S. capital markets envy of the world," he says. "We spent a significant amount of time with FINRA and SEC Staff on productive discussions working through the use of distributed ledger technology and how it can be implemented to provide convenient yet secure platform."

Iownit.us represents a more modern approach to traditional investing processes in an increasingly digitized world.

"We are not here to 'revolutionize' investing, but we do intend to make it vastly more modern and less complicated for both issuers and investors to engage and transact," he says in the release.

In June, the company closed a $4.5 million Seed round of investment. Kurbanov said that those funds would be use to wrap up this approval process. Now that it's all squared away, the remaining funds will go toward business development and marketing initiatives and technological advancements.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted